Aegle Therapeutics Corporation is an Arlington and Miami-based biotechnology company developing extracellular vesicles, including exosomes, secreted by mesenchymal stem cells as therapies for dystrophic epidermolysis bullosa and other severe dermatological conditions. Led by CEO Shelley Hartman, the company is developing AGLE-102 and anticipates entering the clinic with AGLE-102 in early 2021. Aegle completed a $6.5M Series A financing to advance its development programs. The company's core product approach centers on leveraging stem-cell–derived extracellular vesicles as therapeutic agents. Aegle also announced the appointment of Heidi Kempinski as Senior Vice President, Head of Operations; she brings over 25 years of global drug development experience, including roles at GSK and as an initial TESARO management team member.

Total raised

$7M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2020